308 results on '"A. Seferian"'
Search Results
2. Assessing self-regulated processes: what do primary school students do, say and think in the process of understanding a text?
3. European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17–19, 2023, Barcelona, Spain
4. Deposition and Dispersal of Human Remains as a Result of Criminal Acts
5. Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial
6. Hypertension pulmonaire associée à la gemcitabine : caractéristiques et évolution
7. Pathogenic DPAGT1 variants in limb‐girdle congenital myasthenic syndrome (LG‐CMS) associated with tubular aggregates and ORAI1 hypoglycosylation
8. Crítica ao Direito do Trabalho Insustentável
9. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer
10. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial
11. Evaristo de Moraes e os direitos da classe trabalhadora na imprensa carioca (1898-1930)
12. The need for carbon emissions-driven climate projections in CMIP7
13. Titin copy number variations associated with dominant inherited phenotypes
14. Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension (CTEPH) with mixed anatomical lesions: a proof of concept
15. P147 Six-year long-term safety and efficacy of Golodirsen in patients with DMD vs mutation-matched external controls
16. P24 Safety and tolerability of Eteplirsen in patients 6–48 Months old with DMD amenable to exon 51 skipping: an open-label extension study
17. P149 Delayed pulmonary progression in Golodirsen-treated patients with Duchenne muscular dystrophy vs mutation-matched external controls
18. Comparing the Safety Action Feedback and Engagement (SAFE) Loop with an established incident reporting system: Study protocol for a pragmatic cluster randomized controlled trial
19. Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study
20. Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study
21. Sarcoidosis-Associated Pulmonary Hypertension
22. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping
23. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
24. Medication Safety Event Reporting
25. Understanding ultrarare adverse events - Lessons learned from a twelve-year review of intraoperative deaths at an academic medical center
26. T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy
27. Irreversible loss in marine ecosystem habitability after a temperature overshoot
28. Étude multicentrique cas témoins de l’efficacité en vie réelle de l’association chimiothérapie immunothérapie dans les cancers bronchiques à petites cellules disséminés
29. 1053: IMPROVING PICU PATIENT SAFETY BY IMPLEMENTING A ROBUST SUPPLY CHAIN MANAGEMENT PROCESS
30. A IMPORTÂNCIA DO “CONHECIMENTO DO TEMA” NA FORMAÇÃO INICIAL DE PROFESSORES E PARA A ELABORAÇÃO DOS CURRÍCULOS A PARTIR DA BASE NACIONAL COMUM CURRICULAR (BNCC)
31. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
32. Correction to: Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen
33. Advance Care Planning in Patients With Metastatic Cancer: A Quality Improvement Initiative
34. VP.24 T Cell-mediated immune response to dystrophin in Duchenne muscular dystrophy - A natural history study
35. O.06 Long term outcomes for X-Linked myotubular Myopathy (XLMTM) with gene replacement therapy, resamirigene bilparvovec: Preliminary results from ASPIRO
36. FP.12 Application for primary endpoint qualification of the 95th centile of stride velocity (SV95C) in Duchenne muscular dystrophy
37. Armenia
38. Middle East and North Africa
39. Entre crises de civilização: ascenso e ocaso das funções capitalistas do Direito Do Trabalho e as novas tarefas tático-ambientais da proteção jurídica das trabalhadoras e trabalhadores
40. Comprehensive Induction Motor Fault Diagnosis Using Extremum Seeking Control
41. Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units
42. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening
43. Incipient Residual-Based Anomaly Detection in Power Electronic Devices
44. An emerging phenotype of pulmonary arterial hypertension patients carryingSOX17variants
45. Improved Respiratory Outcomes for X-Linked Myotubular Myopathy (XLMTM) with Gene Replacement Therapy, Resamirigene Bilparvovec (ASPIRO): Preliminary Results from ASPIRO, a Phase 1/2/3 Study
46. Deciphering a New Phenotype of Pulmonary Arterial Hypertension in Patients Carrying SOX17 Variants
47. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen
48. OP018: ASPIRO gene therapy trial in X-Linked Myotubular Myopathy (XLMTM): Update on preliminary efficacy and safety findings
49. OP024: Discovery and therapeutic implications of pathogenic retroelements in neurodegenerative diseases
50. Prática docente e construção de conceitos em Geografia – contribuições para o ensino de Geografia nas séries iniciais
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.